Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

Abstract Introduction Natalizumab, a therapy for relapsing–remitting multiple sclerosis (RRMS), is associated with a risk of progressive multifocal leukoencephalopathy (PML). Over the last several years, practitioners have used off-label extended interval dosing (EID) of natalizumab to reduce PML ri...

Descripció completa

Dades bibliogràfiques

Autors principals:	Juliette Pelle, Anais R. Briant, Pierre Branger, Nathalie Derache, Charlotte Arnaud, Christine Lebrun-Frenay, Mikael Cohen, Lydiane Mondot, Jerome De Seze, Kevin Bigaut, Nicolas Collongues, Laurent Kremer, Damien Ricard, Flavie Bompaire, Charlotte Ohlmann, Magali Sallansonnet-Froment, Jonathan Ciron, Damien Biotti, Beatrice Pignolet, Jean-Jacques Parienti, Gilles Defer
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2023-02-01
Col·lecció:	Neurology and Therapy
Matèries:	Extended interval dosing Multiple sclerosis Natalizumab Real-world evidence
Accés en línia:	https://doi.org/10.1007/s40120-023-00440-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!